News

Deal Announcements

3-V Biosciences Sees $12 Million VC Funding

Tuesday, December 13, 2011 5:30:00 AM PDT | VentureDeal Staff
   Menlo Park, California  --  3-V Biosciences has secured $12 million in new venture capital investment, according to an SEC regulatory filing.

3-V is developing drugs that are focused on the treatment of infectious diseases, with a lead drug for the treatment of chronic Hepatitis C.

Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.

3-V is still seeking an additional $13 million in funding, according to the filing.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1